Drug Profile
Research programme: renal cancer therapeutic - Stanford University School of Medicine
Alternative Names: STF-62247Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Stanford University School of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Renal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Renal-cancer in USA
- 08 Jul 2008 Preclinical trials in Renal cancer in USA (unspecified route)